Wall Street analysts expect Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) to announce sales of $80,000.00 for the current quarter, according to Zacks. Three analysts have made estimates for Bellicum Pharmaceuticals’ earnings. The highest sales estimate is $100,000.00 and the lowest is $30,000.00. Bellicum Pharmaceuticals reported sales of $100,000.00 in the same quarter last year, which would suggest a negative year-over-year growth rate of 20%. The business is expected to announce its next quarterly earnings report after the market closes on Tuesday, August 8th.

On average, analysts expect that Bellicum Pharmaceuticals will report full-year sales of $80,000.00 for the current fiscal year, with estimates ranging from $220,000.00 to $500,000.00. For the next fiscal year, analysts forecast that the company will report sales of $810,000.00 per share, with estimates ranging from $120,000.00 to $2.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by $0.10. The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.09 million. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 63.42%. The firm’s quarterly revenue was up 39.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.56) EPS.

Several research analysts recently weighed in on the stock. BidaskClub lowered shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Cantor Fitzgerald set a $32.00 price objective on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 24th. Wells Fargo & Company restated an “outperform” rating and set a $31.00 target price on shares of Bellicum Pharmaceuticals in a report on Tuesday, June 27th. Ladenburg Thalmann Financial Services set a $31.00 target price on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. Finally, Jefferies Group LLC dropped their target price on shares of Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $28.43.

In other Bellicum Pharmaceuticals news, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $11.54, for a total transaction of $115,400.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Alan A. Musso sold 6,311 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $12.24, for a total transaction of $77,246.64. The disclosure for this sale can be found here. Insiders have sold a total of 30,571 shares of company stock worth $367,295 over the last 90 days. Corporate insiders own 23.30% of the company’s stock.

A number of hedge funds have recently made changes to their positions in BLCM. Ronald Blue & Co. LLC bought a new stake in shares of Bellicum Pharmaceuticals during the second quarter valued at approximately $117,000. Clear Harbor Asset Management LLC acquired a new stake in Bellicum Pharmaceuticals during the second quarter worth about $118,000. Knott David M acquired a new stake in Bellicum Pharmaceuticals during the first quarter worth about $131,000. Eagle Ridge Investment Management acquired a new stake in Bellicum Pharmaceuticals during the first quarter worth about $144,000. Finally, American International Group Inc. increased its stake in Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 852 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Bellicum Pharmaceuticals (BLCM) opened at 10.88 on Tuesday. The firm’s market cap is $360.16 million. The firm has a 50-day moving average of $11.88 and a 200 day moving average of $12.49. Bellicum Pharmaceuticals has a 1-year low of $9.71 and a 1-year high of $23.11.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/bellicum-pharmaceuticals-inc-nasdaqblcm-expected-to-announce-quarterly-sales-of-80000-00.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.